{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T06:20:28Z","timestamp":1787466028683,"version":"build-2736575974"},"reference-count":30,"publisher":"Akademiai Kiado Zrt.","issue":"34","license":[{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,8,23]]},"abstract":"\n Bevezet\u00e9s:<\/jats:italic>\n A migr\u00e9nes roham kezel\u00e9s\u00e9nek val\u00f3s klinikai\n gy\u00f3gyszerhaszn\u00e1lati mint\u00e1zatair\u00f3l orsz\u00e1gos szinten kev\u00e9s adat \u00e1ll rendelkez\u00e9sre.\n Az eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si adatb\u00e1zisok lehet\u0151s\u00e9get adnak a gy\u00f3gyszerfelhaszn\u00e1l\u00e1s\n d\u00f3zisegys\u00e9g-alap\u00fa, \u00f6sszehasonl\u00edthat\u00f3 elemz\u00e9s\u00e9re.\n C\u00e9lkit\u0171z\u00e9s:<\/jats:italic>\n Orsz\u00e1gos eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si adatb\u00e1zis felhaszn\u00e1l\u00e1s\u00e1val vizsg\u00e1ltuk a migr\u00e9nes\n roham gy\u00f3gyszeres kezel\u00e9s\u00e9nek alakul\u00e1s\u00e1t, a tript\u00e1nkezel\u00e9s perzisztenci\u00e1j\u00e1t,\n valamint a d\u00f3zisegys\u00e9g-alap\u00fa akut gy\u00f3gyszerhaszn\u00e1lati kateg\u00f3ri\u00e1k id\u0151beli\n v\u00e1ltoz\u00e1s\u00e1t.\n M\u00f3dszer:<\/jats:italic>\n Retrospekt\u00edv, longitudin\u00e1lis vizsg\u00e1latot\n v\u00e9gezt\u00fcnk a Nemzeti Eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si Alapkezel\u0151 orsz\u00e1gos gy\u00f3gyszerkiv\u00e1lt\u00e1si\n adatb\u00e1zis\u00e1nak felhaszn\u00e1l\u00e1s\u00e1val. A vizsg\u00e1latba 7840, kor\u00e1bban tript\u00e1nt nem\n alkalmaz\u00f3 beteget vontunk be. A gy\u00f3gyszerfelhaszn\u00e1l\u00e1st h\u00e1rom h\u00f3napos\n id\u0151szakokban \u00e9rt\u00e9kelt\u00fck. A kiv\u00e1ltott migr\u00e9nspecifikus \u00e9s nemszteroid\n gyullad\u00e1scs\u00f6kkent\u0151 k\u00e9sz\u00edtm\u00e9nyek mennyis\u00e9ge alapj\u00e1n akut gy\u00f3gyszerhaszn\u00e1lati\n kateg\u00f3ri\u00e1kat alak\u00edtottunk ki. A kezel\u00e9s megszak\u00edt\u00e1s\u00e1t 90 napot meghalad\u00f3\n kiv\u00e1lt\u00e1si sz\u00fcnetk\u00e9nt defini\u00e1ltuk.\n Eredm\u00e9nyek:<\/jats:italic>\n A tript\u00e1nind\u00edt\u00e1st\n k\u00f6vet\u0151 els\u0151 h\u00e1rom h\u00f3napban a betegek 36,7%-a a gy\u00f3gyszert\u00falhaszn\u00e1lati mint\u00e1zat\n kateg\u00f3ri\u00e1j\u00e1ba, m\u00edg 49,4%-uk a kis rohamter\u00e1pia-terhel\u00e9s kateg\u00f3ri\u00e1j\u00e1ba tartozott\n a v\u00e9nyk\u00f6teles kiv\u00e1lt\u00e1sok eredm\u00e9nyei alapj\u00e1n. Az ut\u00e1nk\u00f6vet\u00e9s sor\u00e1n a betegek\n mintegy 70%-\u00e1n\u00e1l nem t\u00f6rt\u00e9nt tov\u00e1bbi receptk\u00f6teles akut gy\u00f3gyszerkiv\u00e1lt\u00e1s. A\n kezdetben nagy gy\u00f3gyszert\u00falhaszn\u00e1lati ar\u00e1ny a k\u00e9s\u0151bbiekben cs\u00f6kkent, ugyanakkor\n a betegek 16\u201318%-\u00e1n\u00e1l tart\u00f3san fennmaradt. Azokn\u00e1l a betegekn\u00e9l, akik kezdetben\n nagyobb ar\u00e1nyban alkalmaztak tript\u00e1nt a nem specifikus f\u00e1jdalomcsillap\u00edt\u00f3khoz\n k\u00e9pest, kisebb ar\u00e1nyban volt megfigyelhet\u0151 k\u00e9s\u0151bbi gy\u00f3gyszert\u00falhaszn\u00e1lati\n mint\u00e1zat. A tript\u00e1nkezel\u00e9s perzisztenci\u00e1ja gyorsan cs\u00f6kkent: a betegek 14,4%-a a\n 90. napon, m\u00edg 5,3%-a egy \u00e9v eltelt\u00e9vel is kiv\u00e1ltott tript\u00e1nt.\n K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n A d\u00f3zisegys\u00e9g-alap\u00fa kategoriz\u00e1l\u00e1s alkalmas\n lehet a migr\u00e9nhez t\u00e1rs\u00edthat\u00f3 akut gy\u00f3gyszerhaszn\u00e1lati mint\u00e1zatok popul\u00e1ci\u00f3szint\u0171\n vizsg\u00e1lat\u00e1ra. A modell hozz\u00e1j\u00e1rulhat a gy\u00f3gyszerterhel\u00e9s struktur\u00e1lt le\u00edr\u00e1s\u00e1hoz\n \u00e9s a hazai migr\u00e9nell\u00e1t\u00e1s gy\u00f3gyszerhaszn\u00e1lati adatainak monitoroz\u00e1s\u00e1hoz. Orv\n Hetil. 2026; 167(34): 1343\u20131352.\n <\/jats:p>","DOI":"10.1556\/650.2026.33613","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T05:23:31Z","timestamp":1787462611000},"page":"1343-1352","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Tript\u00e1nkezel\u00e9s migr\u00e9nben: d\u00f3zisegys\u00e9g-alap\u00fa modell a perzisztencia \u00e9s az akut gy\u00f3gyszerhaszn\u00e1lati mint\u00e1zatok vizsg\u00e1lat\u00e1ra orsz\u00e1gos eg\u00e9szs\u00e9gbiztos\u00edt\u00e1si adatok alapj\u00e1n"],"prefix":"10.1556","volume":"167","author":[{"given":"\u00c1gnes","family":"Lubik","sequence":"first","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Foglalkoz\u00e1s-orvostani Int\u00e9zet P\u00e9cs, R\u00e1k\u00f3czi \u00fat 2., 7623 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antal","family":"Tibold","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Foglalkoz\u00e1s-orvostani Int\u00e9zet P\u00e9cs, R\u00e1k\u00f3czi \u00fat 2., 7623 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Blasszauer","sequence":"additional","affiliation":[{"name":"MedicalScan Kft. Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel","family":"Reibl","sequence":"additional","affiliation":[{"name":"MedicalScan Kft. Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Komka","sequence":"additional","affiliation":[{"name":"MedicalScan Kft. Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ron","family":"Bartha","sequence":"additional","affiliation":[{"name":"Petz Alad\u00e1r Egyetemi Oktat\u00f3 K\u00f3rh\u00e1z, Neurol\u00f3giai Oszt\u00e1ly Gy\u0151r Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8639-0219","authenticated-orcid":true,"given":"Gergely","family":"Feh\u00e9r","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Foglalkoz\u00e1s-orvostani Int\u00e9zet P\u00e9cs, R\u00e1k\u00f3czi \u00fat 2., 7623 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369\n diseases and injuries in 204 countries and territories, 1990-2019: a systematic\n analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396:\n 1204-1222. Erratum: Lancet 2020; 396: 1562."},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second\n among the world\u2019s causes of disability, and first among young women: findings\n from GBD 2019. J Headache Pain 2020; 21: 137.\n https:\/\/doi.org\/10.1186\/s10194-020-01208-0","DOI":"10.1186\/s10194-020-01208-0"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"B\u00e1nk J, M\u00e1rton S. Hungarian migraine epidemiology. Headache: J Head\n Face Pain 2000; 40: 164-169.\n https:\/\/doi.org\/10.1046\/j.1526-4610.2000.00023.x","DOI":"10.1046\/j.1526-4610.2000.00023.x"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Arnold M. Headache Classification Committee of the International\n Headache Society. The International Classification of Headache Disorders. 3rd\n edition (ICHD-3). Cephalalgia 2018; 38: 1-211.\n https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Cammarota F, De Icco R, Vaghi G, et al. High-frequency episodic\n migraine: Time for its recognition as a migraine subtype? Cephalalgia 2024; 44:\n 3331024241291578.\n https:\/\/doi.org\/10.1177\/03331024241291578","DOI":"10.1177\/03331024241291578"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence,\n disability, and sociodemographic factors: results from the American migraine\n prevalence and prevention study. Headache 2012; 52: 1456-1470.\n https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02223.x","DOI":"10.1111\/j.1526-4610.2012.02223.x"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Ha WS, Jeong JW, Song S, et al. Trends in triptan usage in Korea: a\n population-based cohort study. J Korean Med Sci. 2024; 39: e222.\n https:\/\/doi.org\/10.3346\/jkms.2024.39.e222","DOI":"10.3346\/jkms.2024.39.e222"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Davidsson OB, Olofsson IA, Kogelman LJ, et al. Twenty-five years of\n triptans - a nationwide population study. Cephalalgia 2021; 41: 894-904.\n https:\/\/doi.org\/10.1177\/0333102421991809","DOI":"10.1177\/0333102421991809"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Kati\u0107 BJ, Rajagopalan S, Ho TW, et al. Triptan persistency among\n newly initiated users in a pharmacy claims database. Cephalalgia 2011; 31:\n 488-500. https:\/\/doi.org\/10.1177\/0333102410383058","DOI":"10.1177\/0333102410383058"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Shewale AR, Brandenburg JA, Burslem K, et al. Health care resource\n utilization and costs associated with diagnosed medication overuse headache and\n potential acute medication overuse in individuals with migraine. Cephalalgia\n 2024; 44: 3331024241235139.\n https:\/\/doi.org\/10.1177\/03331024241235139","DOI":"10.1177\/03331024241235139"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Donnet A, Emery C, Aly S, et al. Migraine burden and costs in\n France: a nationwide claims database analysis of triptan users. J Med Econ.\n 2019; 22: 616-624.\n https:\/\/doi.org\/10.1080\/13696998.2019.1590841","DOI":"10.1080\/13696998.2019.1590841"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Zebenholzer K, Gall W, W\u00f6ber C. Use and overuse of triptans in\n Austria. A survey based on nationwide healthcare claims data. J Headache Pain\n 2018; 19: 34.\n https:\/\/doi.org\/10.1186\/s10194-018-0864-0","DOI":"10.1186\/s10194-018-0864-0"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Lipton RB, Marcus SC, Shewale AR, et al. Acute treatment patterns in\n patients with migraine newly initiating a triptan. Cephalalgia 2020; 40:\n 437-447. https:\/\/doi.org\/10.1177\/0333102420905307","DOI":"10.1177\/0333102420905307"},{"key":"R14","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC\/DDD\n Index 2023. World Health Organization, Oslo, 2023."},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Orlando V, Mucherino S, Monetti VM, et al. Treatment patterns and\n medication adherence among newly diagnosed patients with migraine: a drug\n utilisation study. BMJ Open 2020; 10: e038972.\n https:\/\/doi.org\/10.1136\/bmjopen-2020-038972","DOI":"10.1136\/bmjopen-2020-038972"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Ojo A, Zhang S, Bleibdrey N, et al. Persistence and switching\n patterns of migraine prophylactic medications in Canada: a retrospective claims\n analysis comparing adherence and evaluating the economic burden of illness. J\n Pharm Pharm Sci. 2023; 25: 402-417.\n https:\/\/doi.org\/10.18433\/jpps33158","DOI":"10.18433\/jpps33158"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Deighton AM, Harris LA, Johnston K, et al. The burden of medication\n overuse headache and patterns of switching and discontinuation among triptan\n users: a systematic literature review. BMC Neurol. 2021; 21: 425.\n https:\/\/doi.org\/10.1186\/s12883-021-02451-x","DOI":"10.1186\/s12883-021-02451-x"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Barer Y, Hoshen M, Gazit S, et al. Triptan use and potential\n undertreatment in migraine: a retrospective cohort study. J Clin Med. 2026; 15:\n 1437. https:\/\/doi.org\/10.3390\/jcm15041437","DOI":"10.3390\/jcm15041437"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"B\u00e1nk G, Kapus K, M\u00e9sz\u00e1ros J, et al. Framingham risk stratification\n of middle-aged migraineurs. Behav Neurol. 2020; 2020: 7351214.\n https:\/\/doi.org\/10.1155\/2020\/7351214","DOI":"10.1155\/2020\/7351214"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Huang Y, Yan W, Jia Y, et al. Migraine and increased cardiovascular\n disease risk: interaction with traditional risk factors and lifestyle factors. J\n Headache Pain 2025; 26: 92.\n https:\/\/doi.org\/10.1186\/s10194-025-02002-6","DOI":"10.1186\/s10194-025-02002-6"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Antman EM. Evaluating the cardiovascular safety of nonsteroidal\n anti-inflammatory drugs. Circulation 2017; 135: 2062-2072.\n https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.027288","DOI":"10.1161\/CIRCULATIONAHA.117.027288"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Gendolla A, Rauer N, Kraemer S, et al. Epidemiology, demographics,\n triptan contraindications, and prescription patterns of patients with migraine:\n a German claims database study. Neurol Ther. 2022; 11: 167-183.\n https:\/\/doi.org\/10.1007\/s40120-021-00304-w","DOI":"10.1007\/s40120-021-00304-w"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Pero A, Pace A, Dhamoon MS. Triptan medication use among patients\n with migraine with contraindications in the US. Headache 2022; 62: 883-889.\n https:\/\/doi.org\/10.1111\/head.14327","DOI":"10.1111\/head.14327"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Fejes E, Feh\u00e9r G, Gurdan Z, et al. Characteristics of patients\n referred to a specialized headache clinic. Sci Rep. 2020; 10: 1146.\n https:\/\/doi.org\/10.1038\/s41598-020-58234-w","DOI":"10.1038\/s41598-020-58234-w"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Fitzek MP, Overeem LH, Ulrich M, et al. Differences in\n pharmacological migraine treatment across different levels of clinical headache\n care - a cross-sectional study. J Headache Pain 2025; 26: 78.\n https:\/\/doi.org\/10.1186\/s10194-025-02027-x","DOI":"10.1186\/s10194-025-02027-x"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Dodick DW. Triptan nonresponder studies: implications for clinical\n practice. Headache 2005; 45: 156-162.\n https:\/\/doi.org\/10.1111\/j.1526-4610.2005.05031.x","DOI":"10.1111\/j.1526-4610.2005.05031.x"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Mathew PG, Pavlovic JM, Lettich A, et al. Education and decision\n making at the time of triptan prescribing: patient expectations vs actual\n practice. Headache 2014; 54: 698-708.\n https:\/\/doi.org\/10.1111\/head.12308","DOI":"10.1111\/head.12308"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Kristoffersen ES, Lundqvist C. Medication-overuse headache:\n epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014; 5: 87-99.\n https:\/\/doi.org\/10.1177\/2042098614522683","DOI":"10.1177\/2042098614522683"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Issi ZT, Duran H, Ku\u015f ME, et al. Medication overuse headache and\n awareness. Arq Neuropsiquiatr. 2021; 79: 1095-1100.\n https:\/\/doi.org\/10.1590\/0004-282x-anp-2020-0547","DOI":"10.1590\/0004-282x-anp-2020-0547"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Bailey NN, Herndon CM, Cruz TD. Medication overuse headache in the\n US: a national cross-sectional survey. J Pain Palliat Care Pharmacother. 2025;\n 39: 468-476.\n https:\/\/doi.org\/10.1080\/15360288.2025.2538517","DOI":"10.1080\/15360288.2025.2538517"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/34\/article-p1343.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/34\/article-p1343.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/34\/article-p1343.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T05:23:33Z","timestamp":1787462613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/34\/article-p1343.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,23]]},"references-count":30,"journal-issue":{"issue":"34"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33613","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,23]]}}}